Theranostics

Theranostics Market Outlook

The global Theranostics market was valued at approximately USD 10.5 billion in 2022 and is projected to reach around USD 25 billion by 2035, growing at a remarkable CAGR of 12.5% during the forecast period from 2025 to 2035. This rapid growth can be attributed to the increasing demand for personalized medicine, advancements in medical imaging technologies, and the expanding applications of theranostics in treating various diseases. The integration of diagnostic and therapeutic agents into single treatment processes is revolutionizing patient management, allowing for more targeted therapies and better patient outcomes. Furthermore, the rising prevalence of chronic diseases such as cancer and neurological disorders is propelling the demand for advanced theranostic solutions. The burgeoning investments in research and development and the growing collaboration between pharmaceutical companies and research institutions are also significant contributors to the market's growth trajectory.

Growth Factor of the Market

The increasing prevalence of cancer and other chronic diseases is one of the primary growth factors driving the Theranostics market. As the global population ages, the incidence of diseases requiring precise diagnostics and targeted therapeutic interventions continues to escalate, necessitating innovative solutions like theranostics. Moreover, advancements in imaging technologies, such as PET, MRI, and CT scans, are enhancing the efficacy and accuracy of theranostic applications, thereby enabling healthcare providers to deliver personalized treatment plans tailored to individual patient needs. The rising emphasis on personalized medicine, which seeks to customize healthcare delivery based on genetic, environmental, and lifestyle factors, is also fostering the demand for theranostic agents. Additionally, the expanding research efforts focused on integrating diagnostics with therapeutic applications are stimulating market growth, as they offer the promise of improved patient outcomes and reduced healthcare costs. Furthermore, the acceptance of theranostics across various healthcare settings, including hospitals and outpatient clinics, underscores its significant potential in transforming patient care.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 12.5% from 2025 to 2035, reflecting a robust demand for personalized treatment solutions.
• Oncology remains the dominant application segment, driven by the increasing incidence of cancer worldwide.
• North America is expected to hold the largest market share, supported by advanced healthcare infrastructure and high R&D investments.
• Emerging economies in the Asia Pacific region are anticipated to witness substantial growth due to rising healthcare spending and improving access to diagnostics.
• Combined theranostics products are gaining traction, offering enhanced efficacy by integrating imaging and therapeutic capabilities.

By Product Type

Imaging Agents:

Imaging agents are critical components of the theranostics market, facilitating the visualization of biological processes for diagnostic purposes. These agents, which include radiotracers and contrast agents, are used in conjunction with advanced imaging techniques to provide real-time insights into a patient’s condition. The growing demand for precise imaging in oncology and other fields is driving innovations in imaging agents, leading to the development of novel products that improve diagnostic accuracy and therapeutic outcomes. For instance, agents that can specifically bind to cancerous cells are being researched and developed, allowing for targeted imaging and enhanced treatment options. Furthermore, the increasing use of molecular imaging techniques, which offer higher sensitivity and specificity, is further propelling the market for imaging agents within the theranostics landscape.

Diagnostic Kits:

Diagnostic kits play a crucial role in the theranostics market by enabling the identification and monitoring of disease states. These kits are designed to provide rapid, accurate results, allowing healthcare providers to make informed decisions regarding patient management. The rising prevalence of diseases such as cancer and infectious diseases is significantly boosting the demand for diagnostic kits, as early detection and monitoring are vital for effective treatment. The development of point-of-care diagnostic kits has further enhanced accessibility and convenience, particularly in remote areas and developing regions. As the healthcare landscape evolves, the trend towards decentralized testing and at-home diagnostics is anticipated to drive innovations in diagnostic kits, making them an essential component of personalized medicine.

Therapeutic Agents:

Therapeutic agents in the theranostics market encompass a range of treatment modalities designed to address specific diseases based on individual patient profiles. These agents are developed to target particular cellular pathways or mechanisms of action, providing personalized treatment options that minimize side effects and enhance therapeutic efficacy. The continuous advancements in biotechnology and pharmacology are facilitating the introduction of novel therapeutic agents that can be paired with diagnostic tools, thus enhancing patient care. For instance, targeted therapies that are linked to specific biomarkers are becoming increasingly prevalent in oncology, allowing for more effective treatment strategies. The growing focus on personalized therapy underscores the importance of therapeutic agents in the theranostics market, with ongoing research aimed at expanding their applications across various disease states.

Combined Theranostics:

Combined theranostics represent a revolutionary approach in the treatment of diseases, integrating both diagnostic and therapeutic functions into a single agent. This dual-functionality not only enhances the precision of treatment but also improves patient adherence by streamlining the treatment process. The ability to visualize and treat disease simultaneously is particularly advantageous in oncology, where such agents can offer insights into tumor behavior and response to therapy in real time. The growing body of research exploring the efficacy of combined theranostics is likely to fuel further innovations and product development in this area. As healthcare providers increasingly seek methods to improve patient outcomes and reduce costs, the adoption of combined theranostic products is expected to rise, marking a significant shift in the paradigm of disease management.

By Application

Oncology:

Oncology represents one of the most significant application segments in the theranostics market, driven by the urgent need for effective cancer diagnosis and treatment. The increasing incidence of various cancers worldwide necessitates the development of targeted therapies that can efficiently address tumor characteristics. Theranostic approaches in oncology allow for the identification of specific cancer types and the tailoring of treatment regimens to individual patient needs. The use of imaging agents in conjunction with therapeutic agents facilitates real-time monitoring of treatment responses, enabling healthcare providers to make timely adjustments to therapy. Furthermore, the discovery of new biomarkers and advancements in genomic profiling are enhancing the capabilities of theranostics in oncology, contributing to improved patient outcomes and survival rates.

Cardiovascular Diseases:

The application of theranostics in cardiovascular diseases is emerging as a promising area, as it enables the precise diagnosis and management of various heart-related conditions. By integrating imaging technologies with therapeutic interventions, healthcare providers can obtain comprehensive insights into cardiovascular health, facilitating the early detection of diseases such as heart failure and coronary artery disease. The development of theranostic agents that specifically target cardiovascular biomarkers is enhancing the ability to monitor disease progression and tailor treatment strategies. Additionally, the increasing prevalence of lifestyle-related cardiovascular conditions is driving the demand for innovative therapeutic solutions that can improve patient adherence and outcomes. As research in this area continues to evolve, the role of theranostics in cardiovascular medicine is expected to grow significantly.

Neurological Disorders:

Neurological disorders represent a complex set of diseases that significantly impact the quality of life. The application of theranostics in this field offers the potential for tailored diagnostic and therapeutic strategies that can help manage conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. By leveraging advanced imaging techniques and biomarkers, theranostic approaches can provide a more comprehensive understanding of disease mechanisms, facilitating earlier diagnosis and personalized treatment plans. The ongoing research into the pathophysiology of neurological disorders is driving the development of new theranostic agents that can target specific pathways, offering hope for improved treatment outcomes. As the understanding of these complex diseases continues to advance, the integration of theranostics is likely to play a critical role in reshaping the management of neurological disorders.

Infectious Diseases:

The rise of infectious diseases, particularly in the context of global pandemics, has underscored the urgent need for effective diagnostic and therapeutic solutions. Theranostics is increasingly being recognized for its potential in the early detection and treatment of infectious diseases, enabling healthcare providers to tailor interventions based on individual patient profiles. The integration of rapid diagnostic tests with targeted therapeutic agents offers a dual approach that can improve patient outcomes and reduce the spread of infections. Ongoing research into the mechanisms of various pathogens is facilitating the development of novel theranostic agents that can specifically target infectious agents while preserving healthy tissues. As the landscape of infectious diseases continues to evolve, the role of theranostics in managing these conditions is expected to gain prominence.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for theranostic products, providing comprehensive diagnostic and therapeutic services to patients. The integration of theranostics in hospital settings enables healthcare providers to utilize advanced imaging technologies and therapeutic interventions in a cohesive manner, improving patient management. Hospitals are increasingly adopting these innovative solutions to enhance the accuracy of diagnoses and tailor treatment plans, particularly in oncology and other critical care areas. The continuous investment in state-of-the-art imaging and therapeutic equipment is further driving the growth of the theranostics market within hospitals. As the demand for personalized medicine grows, hospitals are expected to play a pivotal role in the adoption and implementation of theranostic products.

Diagnostic Laboratories:

Diagnostic laboratories are essential players in the theranostics market, offering specialized testing services that are crucial for effective disease management. These laboratories provide a wide range of diagnostic tests, including biomarker analysis and genomic profiling, which are integral to the development of personalized treatment plans. The growing emphasis on precision medicine is propelling the demand for advanced diagnostic services, with laboratories increasingly investing in cutting-edge technologies to enhance their capabilities. The collaboration between diagnostic laboratories and healthcare providers facilitates the seamless integration of diagnostic results with therapeutic interventions, promoting a more streamlined approach to patient care. As the theranostics market continues to expand, diagnostic laboratories are expected to play a significant role in delivering innovative testing solutions.

Research Institutes:

Research institutes are at the forefront of innovation in the theranostics market, conducting critical studies to explore the efficacy of new diagnostic and therapeutic agents. These institutes are essential for driving advancements in the field, as they work to identify novel biomarkers and develop new theranostic products. The collaboration between research institutes and industry stakeholders fosters the translation of scientific discoveries into practical applications, ultimately benefiting patient care. The increasing investment in biomedical research and the rising number of clinical trials focused on theranostics are further propelling the growth of this segment. As research continues to advance, institutes are expected to play a vital role in shaping the future of theranostics through innovation and discovery.

Others:

The 'Others' segment in the distribution channel category encompasses various platforms through which theranostic products are made available to healthcare providers and patients. This includes online pharmacies, specialty clinics, and purchasing cooperatives that cater to specific needs in the healthcare market. As the demand for individualized treatment options grows, alternative distribution channels are becoming increasingly significant in ensuring that theranostic products reach their intended audiences. The rise of e-commerce in the healthcare sector has also opened new avenues for the distribution of theranostic solutions, allowing for greater accessibility and convenience. The diversification of distribution channels is expected to contribute to the overall growth of the theranostics market by improving product availability and enhancing patient access to cutting-edge therapeutic options.

By Ingredient Type

Nanoparticles:

Nanoparticles are gaining prominence in the theranostics market due to their unique properties that facilitate targeted drug delivery and imaging. These materials can be engineered to interact with biological systems at the cellular level, enabling the development of advanced therapeutic and diagnostic agents. The ability to encapsulate drugs within nanoparticles allows for controlled release, enhancing the efficacy of treatments while minimizing side effects. Moreover, nanoparticles can be functionalized with specific targeting ligands, enabling them to selectively bind to diseased cells, particularly in oncology applications. The ongoing research into the development of innovative nanoparticle-based theranostic agents is expected to drive market growth, as they offer new possibilities for personalized medicine.

Radiotracers:

Radiotracers play a crucial role in the theranostics market by enabling the visualization of biological processes through imaging technologies. These substances are used in conjunction with imaging modalities such as PET and SPECT to provide real-time insights into disease states. The increasing demand for precise diagnostic capabilities is driving advancements in radiotracer development, leading to the introduction of novel agents that can specifically target particular diseases. The integration of radiotracers with therapeutic agents is enhancing the potential of theranostics, offering a dual approach that can improve patient outcomes. As the understanding of disease mechanisms deepens, the future of radiotracers in theranostics looks promising, with ongoing research aimed at expanding their applications.

Biomolecules:

Biomolecules are integral to the theranostics market, providing the basis for many innovative diagnostic and therapeutic solutions. These molecules, which include peptides, proteins, and nucleic acids, are being explored for their potential to target specific disease pathways and facilitate personalized treatment strategies. The advancements in synthetic biology and genomics are driving the development of biomolecule-based theranostic agents that can offer enhanced specificity and efficacy. As the demand for personalized medicine grows, the importance of biomolecules in developing targeted therapies and diagnostics is becoming increasingly evident. The ongoing research efforts in this area are expected to yield significant breakthroughs, further advancing the theranostics landscape.

Contrast Agents:

Contrast agents are critical components in the theranostics market, enhancing the visibility of internal structures during imaging procedures. These agents, which are used in various imaging modalities, including MRI and ultrasound, enable healthcare providers to obtain detailed insights into a patient's condition. The growing demand for advanced imaging solutions is driving innovations in contrast agents, leading to the development of products that offer improved safety and efficacy profiles. The integration of contrast agents in theranostic applications is enhancing diagnostic accuracy and facilitating more tailored therapeutic interventions. As imaging technologies continue to advance, the role of contrast agents in the theranostics market is expected to expand, contributing to improved patient care.

By Region

The Theranostics market exhibits significant regional variations, influenced by factors such as healthcare infrastructure, regulatory frameworks, and disease prevalence. North America currently holds the largest market share, accounting for approximately 40% of the global market. The region's advanced healthcare infrastructure, high levels of R&D investment, and widespread acceptance of personalized medicine are key drivers of this growth. Furthermore, the increasing incidence of chronic diseases, particularly cancer, is propelling the demand for innovative theranostic solutions. The North American market is expected to grow at a CAGR of 12% over the forecast period, reflecting the ongoing advancements in diagnostic and therapeutic technologies.

In contrast, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, with an expected CAGR of 15%. This growth can be attributed to the rapid advancements in healthcare infrastructure, increasing healthcare spending, and rising awareness of personalized medicine. Countries such as China and India are experiencing transformative changes in their healthcare systems, facilitating broader access to advanced diagnostic and therapeutic solutions. Additionally, the rising prevalence of chronic diseases in the region is further driving the demand for theranostic agents, making the Asia Pacific market a key area of focus for industry stakeholders.

Opportunities

The theranostics market presents significant opportunities, particularly in the realm of personalized medicine. As healthcare providers and patients alike increasingly recognize the value of tailored treatment approaches, the demand for theranostic solutions is expected to rise. The continuous advancements in biomarker research and genomic profiling are creating new avenues for developing innovative theranostic agents that can address unmet medical needs across various diseases. Moreover, the growing emphasis on preventive healthcare is further driving the adoption of theranostic applications, as early diagnosis and targeted interventions can lead to improved health outcomes and reduced healthcare costs. The potential for collaboration between pharmaceutical companies, research institutions, and healthcare providers is also a promising opportunity for expanding the reach and impact of theranostic solutions.

Another significant opportunity lies in the rapid technological advancements in imaging and therapeutic modalities. As imaging technologies continue to evolve, the capability to accurately visualize and monitor disease processes is improving, allowing for better integration with therapeutic interventions. The rise of artificial intelligence and machine learning in healthcare is also poised to enhance the development and application of theranostics, enabling more precise diagnostics and predictive analytics for treatment outcomes. Furthermore, the increasing governmental support for research and development in personalized medicine is expected to create a favorable environment for the growth of the theranostics market, as new funding initiatives and regulatory frameworks encourage innovation and collaboration.

Threats

Despite the promising outlook for the theranostics market, several threats could impede its growth. One of the primary concerns is the stringent regulatory environment that governs the approval and commercialization of theranostic products. The complexity of integrating diagnostics and therapeutics into single agents often results in prolonged development timelines and increased costs, potentially deterring investment in this area. Additionally, the high cost of research and development, coupled with the need for extensive clinical trials, poses challenges for smaller players in the market, limiting their ability to compete with larger, well-established companies. Furthermore, the evolving nature of disease mechanisms and the emergence of drug-resistant strains, particularly in infectious diseases, can complicate the effectiveness of existing theranostic agents, necessitating continuous innovation and adaptation.

Another significant threat to the theranostics market is the increasing competition from alternative treatment modalities. As the healthcare landscape evolves, new technologies and treatment approaches are continually being developed, potentially overshadowing traditional theranostic methods. The rise of telemedicine and remote patient monitoring solutions may also alter the demand dynamics for theranostic products, as patients seek more convenient and accessible alternatives. Additionally, the ongoing global economic challenges and fluctuations in healthcare funding may impact the overall investment in theranostics research and development. Addressing these threats effectively will require a concerted effort from industry stakeholders to navigate the complexities of the regulatory landscape and adapt to the changing demands of the healthcare sector.

Competitor Outlook

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Abbott Laboratories
• Bayer AG
• Novartis AG
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Cardinal Health
• Biogen Inc.
• Illumina Inc.
• Covalent Bioscience
• NeuroTherapeutics
• Hologic Inc.

The competitive landscape of the theranostics market is characterized by the presence of both established companies and emerging startups, all striving to innovate and capture market share. Major players such as GE Healthcare, Siemens Healthineers, and Philips Healthcare are leading the charge by investing heavily in research and development, aiming to bring cutting-edge theranostic solutions to market. These companies leverage their extensive experience and established distribution channels to introduce advanced imaging technologies and therapeutic agents that meet the growing demand for personalized medicine. Additionally, collaborations between pharmaceutical companies and diagnostic firms are becoming increasingly common, as they seek to develop integrated theranostic products that address specific disease states.

In particular, companies like Abbott Laboratories and Bayer AG are making significant strides in the development of novel theranostic agents for oncology and cardiovascular applications. Abbott's focus on precision diagnostics and Bayer's commitment to integrating diagnostics with therapeutic solutions exemplify the strategic shifts taking place within the industry. Furthermore, the emergence of biotechnology firms such as Illumina and Biogen is driving innovation in genomic profiling and biomarker research, essential components of the theranostics landscape. These companies are vigorously pursuing the development of new biomarkers that can enhance the specificity and efficacy of theranostic agents, thereby propelling market growth.

Emerging players like Covalent Bioscience and NeuroTherapeutics are also contributing to the competitive dynamics of the theranostics market by focusing on niche applications and innovative product development. These smaller companies often prioritize agility and specialized expertise, allowing them to respond rapidly to emerging trends and unmet medical needs. As the theranostics market continues to evolve, the competitive landscape is likely to witness increased collaboration, mergers, and acquisitions, as companies strive to strengthen their portfolios and enhance their capabilities in delivering integrated diagnostic and therapeutic solutions. The ongoing advancements in technology and a growing emphasis on personalized medicine are expected to shape the future of this dynamic market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Biogen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hologic Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 GE Healthcare
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Illumina Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Cardinal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 NeuroTherapeutics
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Philips Healthcare
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Abbott Laboratories
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Covalent Bioscience
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Siemens Healthineers
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Theranostics Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Cardiovascular Diseases
    • 6.1.3 Neurological Disorders
    • 6.1.4 Infectious Diseases
    • 6.1.5 Others
  • 6.2 Theranostics Market, By Product Type
    • 6.2.1 Imaging Agents
    • 6.2.2 Diagnostic Kits
    • 6.2.3 Therapeutic Agents
    • 6.2.4 Combined Theranostics
  • 6.3 Theranostics Market, By Ingredient Type
    • 6.3.1 Nanoparticles
    • 6.3.2 Radiotracers
    • 6.3.3 Biomolecules
    • 6.3.4 Contrast Agents
    • 6.3.5 Others
  • 6.4 Theranostics Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Laboratories
    • 6.4.3 Research Institutes
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Theranostics Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Theranostics market is categorized based on

By Product Type

• Imaging Agents
• Diagnostic Kits
• Therapeutic Agents
• Combined Theranostics

By Application

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Others

By Distribution Channel

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Ingredient Type

• Nanoparticles
• Radiotracers
• Biomolecules
• Contrast Agents
• Others

By Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Abbott Laboratories
• Bayer AG
• Novartis AG
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Cardinal Health
• Biogen Inc.
• Illumina Inc.
• Covalent Bioscience
• NeuroTherapeutics
• Hologic Inc.